A newly developed therapeutic antibody recruits the body’s own immune system to kill cancer cells, offering a new approach to treating acute myeloid leukaemia.
Exciting new cancer research, using data collected from the Australian Synchrotron, could lead to a new approach to the treatment of acute myeloid leukaemia (AML). AML is an aggressive form of cancer affecting the blood and bone marrow, and has poor survival rates. Patients can be treated with chemotherapy to induce remission, but there is a high likelihood of relapse.